title: MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.
abstract: The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.
authors.affiliation: Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA. gsgouros@jhmi.edu
authors.forename: George
authors.initials: G
authors.lastname: Sgouros
authors.forename: John C
authors.initials: JC
authors.lastname: Roeske
authors.forename: Michael R
authors.initials: MR
authors.lastname: McDevitt
authors.forename: Stig
authors.initials: S
authors.lastname: Palm
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Allen
authors.forename: Darrell R
authors.initials: DR
authors.lastname: Fisher
authors.forename: A Bertrand
authors.initials: AB
authors.lastname: Brill
authors.forename: Hong
authors.initials: H
authors.lastname: Song
authors.forename: Roger W
authors.initials: RW
authors.lastname: Howell
authors.forename: Gamal
authors.initials: G
authors.lastname: Akabani
authors.forename: Wesley E
authors.initials: WE
authors.lastname: Bolch
authors.forename: A Bertrand
authors.initials: AB
authors.lastname: Brill
authors.forename: Darrell R
authors.initials: DR
authors.lastname: Fisher
authors.forename: Roger W
authors.initials: RW
authors.lastname: Howell
authors.forename: Ruby F
authors.initials: RF
authors.lastname: Meredith
authors.forename: George
authors.initials: G
authors.lastname: Sgouros
authors.forename: Barry W
authors.initials: BW
authors.lastname: Wessels
authors.forename: Pat B
authors.initials: PB
authors.lastname: Zanzonico
mesh_terms: D000512:Alpha Particles / Q000009:adverse effects / Q000627:therapeutic use*; D016923:Cell Death / Q000528:radiation effects; D002470:Cell Survival / Q000528:radiation effects; D002986:Clinical Trials as Topic; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000532:radiotherapy*; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D010174:Pamphlets; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011853:Radiobiology; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D012062:Relative Biological Effectiveness; D012955:Societies, Medical
chemical_list: D011837:Radiation-Protective Agents; D011868:Radioisotopes